DE69328558T2 - Pharmazeutisches Präparat zur synergistischen Aktivierung natürlicher Killerzellen - Google Patents

Pharmazeutisches Präparat zur synergistischen Aktivierung natürlicher Killerzellen

Info

Publication number
DE69328558T2
DE69328558T2 DE69328558T DE69328558T DE69328558T2 DE 69328558 T2 DE69328558 T2 DE 69328558T2 DE 69328558 T DE69328558 T DE 69328558T DE 69328558 T DE69328558 T DE 69328558T DE 69328558 T2 DE69328558 T2 DE 69328558T2
Authority
DE
Germany
Prior art keywords
pct
natural killer
killer cells
pharmaceutical preparation
date
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69328558T
Other languages
English (en)
Other versions
DE69328558D1 (de
Inventor
Kristoffer Hellstrand
Svante Hermodsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Maxim Pharmaceuticals Inc
Original Assignee
Maxim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxim Pharmaceuticals Inc filed Critical Maxim Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69328558D1 publication Critical patent/DE69328558D1/de
Publication of DE69328558T2 publication Critical patent/DE69328558T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE69328558T 1992-06-03 1993-06-03 Pharmazeutisches Präparat zur synergistischen Aktivierung natürlicher Killerzellen Expired - Fee Related DE69328558T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9201719A SE513429C2 (sv) 1992-06-03 1992-06-03 Preparat för aktivering av naturliga mördarceller, vilket preparat innehåller interferon alfa och biogena aminer
PCT/SE1993/000496 WO1993024144A1 (en) 1992-06-03 1993-06-03 PREPARATION FOR ACTIVATION OF NATURAL KILLER CELLS (NK-CELLS), SAID PREPARATION CONTAINING INTERFERON-α AND HISTAMINE, SEROTONIN OR SUBSTANCES WITH CORRESPONDING RECEPTOR ACTIVITY

Publications (2)

Publication Number Publication Date
DE69328558D1 DE69328558D1 (de) 2000-06-08
DE69328558T2 true DE69328558T2 (de) 2001-01-04

Family

ID=20386405

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69328558T Expired - Fee Related DE69328558T2 (de) 1992-06-03 1993-06-03 Pharmazeutisches Präparat zur synergistischen Aktivierung natürlicher Killerzellen

Country Status (12)

Country Link
US (1) US5728378A (de)
EP (1) EP0652768B1 (de)
JP (1) JP2888259B2 (de)
AT (1) ATE192338T1 (de)
CA (1) CA2136952C (de)
DE (1) DE69328558T2 (de)
DK (1) DK0652768T3 (de)
ES (1) ES2147758T3 (de)
GR (1) GR3033894T3 (de)
PT (1) PT652768E (de)
SE (1) SE513429C2 (de)
WO (1) WO1993024144A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6063373A (en) 1989-09-19 2000-05-16 Maxim Pharmaceuticals, Inc. Enhanced activation of NK cells using an NK cell activator and a hydrogen peroxide scavenger or inhibitor
US6003516A (en) * 1992-06-03 1999-12-21 Maxim Pharmaceuticals, Inc. Method for treatment of cancer and infectious disease
EP0690715B1 (de) * 1993-03-26 2003-05-28 Beth Israel Hospital Association Topische und systemische anwendung von buspiron und seinen derivaten zur behandlung von pathologischen zuständen, die mit immunantworten verbunden sind
EP0775197A1 (de) 1994-08-08 1997-05-28 Maxim Pharmaceuticals, Inc. Verstärkte aktivierung von natürlicher killerzellen durch verwendung von einem fängern oder hemmern des wasserstoffperoxids
US5961969A (en) * 1996-05-14 1999-10-05 Maxim Pharmaceuticals, Inc. Stable circulating histamine levels
AU778012B2 (en) * 1996-05-14 2004-11-11 Maxim Pharmaceuticals, Inc. Administration of histamine for therapeutic purposes
US6071942A (en) 1996-05-14 2000-06-06 Maxim Pharmaceuticals, Inc. Elevation of circulating blood histamine levels
AU765625C (en) * 1998-08-24 2004-11-18 Maxim Pharmaceuticals, Inc. Activation and protection of T-cells (CD4+ and CD8+) using an H2 receptor agonist and other T-cell activating agents
EP0998923A1 (de) * 1998-10-30 2000-05-10 Basf Aktiengesellschaft Verwendung von 5-HT7 Rezeptoragonisten zur Behandlung oder Vorbeugung von Ischämien
CN1155579C (zh) 1998-12-23 2004-06-30 马克西姆药品公司 二盐酸组胺的合成
US6498181B1 (en) * 1999-01-06 2002-12-24 Maxim Pharmaceuticals Synergistic tumorcidal response induced by histamine
US6242473B1 (en) * 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
US6153113A (en) * 1999-02-22 2000-11-28 Cobe Laboratories, Inc. Method for using ligands in particle separation
US6354986B1 (en) 2000-02-16 2002-03-12 Gambro, Inc. Reverse-flow chamber purging during centrifugal separation
DE10053397A1 (de) * 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10066158B4 (de) * 2000-08-24 2007-08-09 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung des Restless-Legs-Syndroms
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
US20030091553A1 (en) * 2001-10-19 2003-05-15 Gehlsen Kurt R. Use of histamine to treat liver disease
JP4808612B2 (ja) * 2003-04-25 2011-11-02 田辺三菱製薬株式会社 アルキレンジオキシベンゼン誘導体を含む経口投与用組成物
WO2005060960A2 (en) * 2003-12-11 2005-07-07 Maxim Pharmaceuticals, Inc. Use of histamine to treat bone disease
WO2006009975A2 (en) * 2004-06-22 2006-01-26 Maxim Pharmaceuticals, Inc. Histamine to treat disorders affecting muscle function
EP1712634A1 (de) * 2005-04-13 2006-10-18 Wittycell SAS Verfahren zur Auswahl von effizienten antigen präsentierenden Zellen und ihre Anwendung in der Regulation der Immunität
SG166716A1 (en) 2009-05-14 2010-12-29 Hsiehs Biotech Singapore Pte Ltd Lycopene and resveratrol compositions for nk cell activation resulting in anti-neoplastic effect
WO2014130759A1 (en) * 2013-02-21 2014-08-28 University Of Rochester Methods of using histamine receptor agonists and antagonists
CN115925920B (zh) * 2022-08-04 2023-07-25 瑞因细胞工程科技(广州)有限公司 一种基因增强型免疫细胞治疗肝硬化的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863727A (en) * 1986-04-09 1989-09-05 Cetus Corporation Combination therapy using interleukin-2 and tumor necrosis factor
EP0295317A1 (de) * 1987-06-16 1988-12-21 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Pharmazeutische Zusammensetzung zur Behandlung von Tumoren
US5215744A (en) * 1987-06-16 1993-06-01 Boehringer Ingelheim Gmbh Methods for the treatment of tumors
US4883661A (en) * 1987-10-09 1989-11-28 Daly John M Use of arginine as an lymphokine synergist
US5026544A (en) * 1988-02-16 1991-06-25 Board Of Reagents, The University Of Texas System Methods and compositions for inhibiting the growth of neoplastic cells

Also Published As

Publication number Publication date
SE9201719D0 (sv) 1992-06-03
US5728378A (en) 1998-03-17
WO1993024144A1 (en) 1993-12-09
GR3033894T3 (en) 2000-11-30
ES2147758T3 (es) 2000-10-01
AU4366093A (en) 1993-12-30
JP2888259B2 (ja) 1999-05-10
EP0652768B1 (de) 2000-05-03
CA2136952A1 (en) 1993-12-09
ATE192338T1 (de) 2000-05-15
SE513429C2 (sv) 2000-09-11
PT652768E (pt) 2000-09-29
DK0652768T3 (da) 2000-08-07
SE9201719L (sv) 1993-12-04
DE69328558D1 (de) 2000-06-08
AU672610B2 (en) 1996-10-10
CA2136952C (en) 2005-08-09
EP0652768A1 (de) 1995-05-17
JPH08502024A (ja) 1996-03-05

Similar Documents

Publication Publication Date Title
ATE192338T1 (de) Pharmazeutisches präparat zur synergistischen aktivierung natürlicher killerzellen
ATE383169T1 (de) Komponente und zusammensetzungen zur verabreichung von wirkstoffen
NO952744D0 (no) Cytokinbegrensende midler
ES2102813T3 (es) Composiciones farmaceuticas y dermocosmeticas que contienen calostro equino.
ATE240721T1 (de) Dosiszusammensetzung mit modifizierter freigabe aus vielen einzelkomponenten
IL87885A (en) Pharmaceutical compositions having antiprogestational and anti-estrogenic activities for the treatment of hormone- dependent tumors
DE69333023D1 (de) 3-beta-hydroxylierte natürliche Steroidderivate enthaltende Arzneimittelzusammensetzungen und ihre Verwendung
PT99513A (pt) Processo para a preparacao de composicoes farmaceuticas contendo profarmacos de morfina para administracao topica por via transdermica
DK0695171T3 (da) Lyosfærer indeholdende gonadotropin
NO952321L (no) Polypeptid, samt anti-HIV-preparat fremstilt fra dette
DE69506007D1 (de) Transdermales system zur gleichzeitigen verabreichung von mehreren wirkstoffen
KR890700125A (ko) 신규 벤즈이미다졸 유도체, 그 제조방법 및 이 화합물을 함유하는 제약 조성물
DE59406938D1 (de) Pharmazeutische zubereitungen mit einem wirkstoff, der modifizierte amidingruppen enthält
ATE154235T1 (de) Kosmetische oder pharmazeutische zusammensetzungen zur topischen anwendung die deacylierten glycerophospholipide enthalten
EP0173664A3 (de) Biologisch aktive Benzimidazolderivate und Verfahren zu ihrer Herstellung
PT101444A (pt) Associacao sinergizante com efeito antagonista dos receptores nk1 e nk2, uso de produtos com actividade antagonista dos receptores nk1 e nk2 na sua preparacao e composicao farmaceutica contendo a referida associacao
ES2083167T3 (es) Sistemas de retardo mejorados para la liberacion retardada temporalmente de substancias de valor medico y/o biologico a partir de un material soporte de deposito.
PL315127A1 (en) Deuterised biologically active substances for percutaneous administration
NO944214L (no) Farmasöytiske preparater for rektal administrering, inneholdende alkylsulfonamider som er HT1-agonister
NZ234451A (en) Benzofuran-substituted 2-imidazoline derivatives and pharmaceutical compositions
DK0722325T3 (da) Præparat til behandling eller forebyggelse af herpes
ATE169021T1 (de) Cephalostatin-analoga und ihre verwendung als antitumormittel
EP0348664A3 (de) Monoacetoacetine enthaltende pharmazeutische Zusammensetzungen zur Behandlung von Tumoren
DK0817643T3 (da) Forbindelser og præparater til administration af aktive midler

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee